Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.47 |
| ▸ | NQO2 | P16083 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363972 | 1.00 | DRD2 (0.53) | DRD2DRD3ACHEMTNR1ACYP19A1 | |
| SCHEMBL4637019 | 0.84 | DRD2 (0.47) | DRD2DRD3ACHEHTR2AHTR2C | |
| SCHEMBL10321961 | 0.84 | DRD2 (0.47) | DRD2DRD3ACHEHTR2AHTR2C | |
| SCHEMBL30715531 | 0.81 | MTNR1A (0.49) | DRD2DRD3MTNR1ACYP19A1CYP11B1 | |
| SCHEMBL30715541 | 0.81 | MTNR1A (0.49) | DRD2DRD3MTNR1ACYP19A1CYP11B1 | |
| SCHEMBL4132717 | 0.81 | MTNR1A (0.49) | DRD2DRD3MTNR1ACYP19A1CYP11B1 | |
| SCHEMBL30563659 | 0.80 | ACHE (0.60) | DRD2DRD3ACHECYP19A1CYP11B1 | |
| SCHEMBL326892 | 0.80 | MTNR1A (0.54) | DRD2DRD3MTNR1ACYP19A1CYP11B1 | |
| SCHEMBL30563644 | 0.80 | ACHE (0.60) | DRD2DRD3ACHECYP19A1CYP11B1 | |
| SCHEMBL2463469 | 0.80 | ACHE (0.60) | DRD2DRD3ACHECYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110217234-A1 | IMAGING LIGANDS | GENERAL ELECTRIC COMPANY | 2011-09-08 | — | — | US | disclosed |
| WO-2010059905-A2 | IMAGING LIGANDS | GENERAL ELECTRIC COMPANY (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-0179855-B1 | DOPAMINE AGONISTS | Whitby Research Incorporated (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0179855-A4 | DOPAMINE AGONISTS. | NELSON RES & DEV COMPANY (US) | 1986-08-21 | — | — | EP | disclosed |
| EP-0179855-A1 | DOPAMINE AGONISTS. | NELSON RES & DEV (US) | 1986-05-07 | — | — | EP | disclosed |
| WO-1985004582-A1 | NOVEL DOPAMINE AGONISTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1985-10-24 | — | — | WO | disclosed |
| US-4540691-A | Dopamine agonists and use thereof | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217234-A1 | IMAGING LIGANDS | DRD2, SLC6A3, DRD3 | DRD2 1/4885DRD3 3/4885ACHE 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.